BioSig Technologies (BSGM) said late Monday that it has signed definitive agreements with an institutional investor for up to $1.1 billion in growth financing.
The deal includes a $100 million sale of senior secured convertible debentures and a $1 billion equity line of credit. The debentures carry a 4% annual interest rate rising to 18% in default, and mature in 24 months, the company said.
The equity line of credit allows BioSig to sell up to $1 billion of stock over 36 months, Biosig said.
Shares of BioSig were up 25% in recent Tuesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。